1.Capasso LL. Antiquity of cancer. Int
J Cancer. 2005;113(1):2-13.
2. Ham SJ, Schraffordt Koops H, van der Graaf WT, van Horn JR,
Postma L, Hoekstra HJ. Historical, current and future aspects of
osteosarcoma treatment. Eur J Surg Oncol. 1998;24(6):584-600.
3. Pizzo PA, Poplack DG. Principles and Practice of
Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams
& Wilkins; 2006.
4. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma:
current challenges and future directions. Expert Rev Anticancer
Ther. 2006;6(7):1075-1085.
5. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic
advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422-441.
6. Kufe DW, Holland JF, Frei E. American Cancer Society. Holland
Frei cancer medicine 7. 7th ed. Hamilton, Ontario; Lewiston,
NY [distributor]: BC Decker; 2006.
7. Ries LAG, SEER Program (National Cancer Institute (U.S.)). Cancer
incidence and survival among children and adolescents: United States
SEER program 1975-1995 [edited by Lynn A. Gloecker
Ries, et al.]. Bethesda, MD: National Cancer Institute,
SEER Program; 1999.
8. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin
North Am. 1997;44(4):973-989.
9. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood
and adolescence. N Engl J Med. 1999;341(5):342-352.
10. Phillips JC, Stephenson B, Hauck M, Dillberger J. Heritability
and segregation analysis of osteosarcoma in the Scottish deerhound. Genomics. 2007;90(3):354-363.
11. Ru G, Terracini B, Glickman LT. Host related risk factors
for canine osteosarcoma. Vet J. 1998;156(1):31-39.
12. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood
osteogenic sarcoma and potential targets for therapeutic development:
meeting summary. Clin Cancer Res. 2003;9(15):5442-5453.
13. Alpert LI, Abaci IF, Werthamer S. Radiation-induced extraskeletal
osteosarcoma. Cancer. 1973;31(6):1359-1363.
14. Chan LL, Czerniak BA, Ginsberg LE. Radiation-induced osteosarcoma
after bilateral childhood retinoblastoma. AJR Am J Roentgenol. 2000;174
(5):1288.
15. Freeman CR, Gledhill R, Chevalier LM, Whitehead VM, Esseltine
DL. Osteogenic sarcoma following treatment with megavoltage radiation
and chemotherapy for bone tumors in children. Med Pediatr
Oncol. 1980;8(4):375-382.
16. Haselow RE, Nesbit M, Dehner LP, Khan FM, McHugh R, Levitt
SH. Second neoplasms following megavoltage radiation in a pediatric
population. Cancer. 1978;42(3):1185-1191.
17. Sim FH, Cupps RE, Dahlin DC, Ivins JC. Postradiation sarcoma
of bone. J Bone Joint Surg Am. 1972;54(7):1479-1489.
18. Varela-Duran J, Dehner LP. Postirradiation osteosarcoma
in childhood. A clinicopathologic study of three cases and review
of the literature. Am J Pediatr Hematol Oncol. 1980;2(3):263-271.
19. MF, Cavenee WK. Retinoblastoma and osteosarcoma: the prototypic
cancer family. Acta Paediatr Jpn. 1987;29(4):526-533.
20.Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma:
a shared chromosomal mechanism revealing recessive predisposition. Proc
Natl Acad Sci U S A. 1985;82(18):6216-6220.
21. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular
tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 1984;91(11):1351-1355.
22. Dunkel IJ, Gerald WL, Rosenfield NS, Strong EW, Abramson
DH, Ghavimi F. Outcome of patients with a history of bilateral retinoblastoma
treated for a second malignancy: the Memorial Sloan-Kettering experience. Med
Pediatr Oncol. 1998;30(1):59-62.
23. Malkin D, Friend SH, Li FP, Strong LC. Germ-line mutations
of the p53 tumor-suppressor gene in children and young adults with
second malignant neoplasms.
N Engl J Med. 1997;336(10):734.
[PubMed: 9045054]
24. Malkin D, Jolly KW, Barbier N, et al. Germline mutations
of the p53 tumor-suppressor gene in children and young adults with
second malignant neoplasms. N Engl J Med. 1992;326(20):1309-1315.
25. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association
between osteosarcoma and deleterious mutations in the RECQL4 gene
in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003;95(9):669-674.
26. Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma
induced by inactivation of Rb and p53 in the osteoblast lineage. Proc
Natl Acad Sci U S A. 2008;105(33):11851-11856.
27. Ellis NA, Groden J, Ye TZ, et al. The Bloom’s syndrome
gene product is homologous to RecQ helicases. Cell. 1995;83(4):655-666.
28. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare
cancers in Werner syndrome (adult progeria). Cancer Epidemiol
Biomarkers Prev. 1996;5(4):239-246.
29. Hansen MF, Nellissery MJ, Bhatia P. Common mechanisms of
osteosarcoma and Paget’s disease. J Bone Miner
Res. 1999;14 Suppl 2:39-44.
30. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget’s
disease of bone. J Bone Miner Res. 2006;21 Suppl
2:P58-63.
31.Gelberg KH, Fitzgerald EF, Hwang S, Dubrow R.
Growth and development and other risk factors for osteosarcoma in
children and young adults. Int J Epidemiol. 1997;26(2):272-278.
32. Carbone M, Rizzo P, Procopio A, et al. SV40-like sequences
in human bone tumors. Oncogene. 1996;13(3):527-535.
33. Yamamoto H, Nakayama T, Murakami H, et al. High incidence
of SV40-like sequences detection in tumour and peripheral blood
cells of Japanese osteosarcoma patients. Br J Cancer. 2000;82(10):1677-1681.
34. Garcea RL, Imperiale MJ. Simian virus 40 infection of humans. J
Virol. 2003;77(9):5039-5045.
35. Mendoza SM, Konishi T, Miller CW. Integration of SV40 in
human osteosarcoma DNA. Oncogene. 1998;17(19):2457-2462.
36. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings
in 73 osteosarcoma specimens and a review of the literature. Cancer
Genet Cytogenet. 1997;95(1):74-87.
37. Lau CC, Harris CP, Lu XY, et al. Frequent amplification
and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes
Chromosomes Cancer. 2004;39(1):11-21.
38. Man TK, Lu XY, Jaeweon K, et al. Genome-wide array comparative
genomic hybridization analysis reveals distinct amplifications in
osteosarcoma.
BMC Cancer. 2004;4:45.
[PubMed: 15298715]
39. Zielenska M, Bayani J, Pandita A, et al. Comparative genomic
hybridization analysis identifies gains of 1p35 approximately p36
and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet. 2001;130(1):14-21.
40. Dorfman HD, Czerniak B. Bone Tumors. St.
Louis, MO: Mosby; 1998.
41. Huvos AG. Bone Tumors: Diagnosis, Treatment, and
Prognosis. 2nd ed. Philadelphia: Saunders; 1991.
42. Dahlin DC, Unni KK. Bone Tumors: General Aspects
and Data on 8,542 Cases. 4th ed. Springfield, IL: Thomas;
1986.
43. Ladanyi M. The emerging molecular genetics of sarcoma translocations.
Diagn
Mol Pathol. 1995; 4(3):162-173.
[PubMed: 7493135]
44. Ladanyi M, Gorlick R. Molecular pathology and molecular
pharmacology of osteosarcoma. Pediatr Pathol Molec Med. 2000;19:22.
45. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas
of adults: state of the translational science. Clin Cancer
Res. 2003;9(6):1941-1956.
46. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms
in patients with retinoblastoma. Br J Cancer. 1986;53(5):661-671.
47. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence
after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278
(15):1262-1267.
48. Benassi MS, Molendini L, Gamberi G, et al. Alteration of
pRb/p16/cdk4 regulation in human osteosarcoma. Int
J Cancer. 1999;84(5):489-493.
49. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum
of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994;54(11):3042-3048.
50. Toguchida J, Ishizaki K, Sasaki MS, et al. Preferential
mutation of paternally derived RB gene as the initial event in sporadic
osteosarcoma. Nature. 1989;338(6211):156-158.
51. Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch
Ophthalmol. 2001;119(11): 1699-1704.
52. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family
syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358-5362.
53. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations
in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.
54. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and
MDM2 alterations in osteosarcomas: correlation with clinicopathologic
features and proliferative rate. Cancer. 1997;79(8):1541-1547.
55. Miller CW, Aslo A, Tsay C, et al. Frequency and structure
of p53 rearrangements in human osteosarcoma. Cancer Res. 1990;50(24):7950-7954.
56. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline
mutations of the p53 tumor suppressor gene in children with osteosarcoma. J
Clin Oncol. 1994;12(5):925-930.
57. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and
spectrum of germline mutations of the p53 gene among patients with
sarcoma. N Engl J Med. 1992;326(20):1301-1308.
58. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis
of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111(3):367-372.
59. Knowles BB, McCarrick J, Fox N, Solter D, Damjanov I. Osteosarcomas
in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid
gene. Am J Pathol. 1990;137(2):259-262.
60. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient
for p53 are developmentally normal but susceptible to spontaneous
tumours. Nature. 1992;356(6366):215-221.
61. Jacks T, Remington L, Williams BO, et al. Tumor spectrum
analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
62. Liu G, McDonnell TJ, Montes de Oca Luna R, et al. High metastatic
potential in mice inheriting a targeted p53 missense mutation. Proc
Natl Acad Sci U S A. 2000;97(8):4174-4179.
63. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of
function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119(6):847-860.
64. Khidr L, Chen PL. RB, the conductor that orchestrates life,
death and differentiation. Oncogene. 2006;25(38):5210-5219.
65. Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse
osteosarcoma, dependent on p53 loss and potentiated by loss of Rb,
mimics the human disease. Genes Dev. 2008;22(12):1662-1676.
66. Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts
are target cells for transformation in c-fos transgenic mice. J
Cell Biol. 1993;122(3):685-701.
67. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic
phenotype by brief inactivation of MYC. Science. 2002;297(5578):102-104.
68. Erfle V, Schmidt J, Strauss GP, Hehlmann R, Luz A. Activation
and biological properties of endogenous retroviruses in radiation
osteosarcomagenesis. Leuk Res. 1986;10(7):905-913.
69. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats
given daily subcutaneous injections of recombinant human parathyroid
hormone (1-34) for 2 years and relevance to human safety. Toxicol
Pathol. 2002;30(3):312-321.
70. Cotterill SJ, Wright CM, Pearce MS, Craft AW. Stature of
young people with malignant bone tumors. Pediatr Blood Cancer. 2004;42(1):59-63.
71. Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology
of osteosarcoma and Ewing’s sarcoma in childhood: a study
of 305 cases by the Children’s Cancer Group. Cancer. 1998;83(7):
1440-1448.
72. Longhi A, Pasini A, Cicognani A, et al. Height as a risk
factor for osteosarcoma. J Pediatr Hematol Oncol. 2005;27(6):314-318.
73. Fraumeni JF, Jr. Stature and malignant tumors of bone in
childhood and adolescence. Cancer. 1967;20(6):967-973.
74. Withrow SJ. Osteosarcoma. Vet Q. 1998;20
Suppl 1:S19-21.
75. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative
aspects of osteosarcoma. Dog versus man. Clin Orthop Relat
Res. 1991(270):159-168.
76. Tjalma RA. Canine bone sarcoma: estimation of relative risk
as a function of body size. J Natl Cancer Inst. 1966;36(6):1137-1150.
77. Cooley DM, Beranek BC, Schlittler DL, Glickman NW, Glickman
LT, Waters DJ. Endogenous gonadal hormone exposure and bone sarcoma
risk.
Cancer Epidemiol Biomarkers Prev. 2002; 11(11):1434-1440.
[PubMed: 12433723]
78. Sutter NB, Bustamante CD, Chase K, et al. A single IGF1
allele is a major determinant of small size in dogs. Science. 2007;316(5821):112-115.
79. Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence
for a novel osteosarcoma tumor-suppressor gene in the chromosome
18 region genetically linked with Paget disease of bone. Am
J Hum Genet. 1998;63(3):817-824.
80. Hansen MR, Moffat JC. Osteosarcoma of the skull base after
radiation therapy in a patient with McCune-Albright syndrome: case
report. Skull Base. 2003;13(2):79-83.
81. Koshy M, Paulino AC, Mai WY, Teh BS. Radiation-induced osteosarcomas
in the pediatric population. Int J Radiat Oncol Biol Phys. 2005;63(4):1169-1174.
82. Kuttesch JF, Jr., Wexler LH, Marcus RB, et al. Second malignancies
after Ewing’s sarcoma: radiation dose-dependency of secondary
sarcomas. J Clin Oncol. 1996;14(10):2818-2825.
83. Shaheen M, Deheshi BM, Riad S, et al. Prognosis of radiation-induced
bone sarcoma is similar to primary osteosarcoma.
Clin Orthop
Relat Res. 2006;450:76-81.
[PubMed: 16906097]
84. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity
of the RB gene is a poor prognostic factor in patients with osteosarcoma. J
Clin Oncol. 1996;14(2):467-472.
85. Toguchida J, Ishizaki K, Sasaki MS, et al. Chromosomal reorganization
for the expression of recessive mutation of retinoblastoma susceptibility
gene in the development of osteosarcoma. Cancer Res. 1988;48(14):3939-3943.
86. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification
in osteosarcoma: reciprocal relationship with INK4A gene alterations
and mapping of 12q13 amplicons. Int J Cancer. 1999;80(2):199-204.
87. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading
frames of the INK4a tumor suppressor gene encode two unrelated proteins
capable of inducing cell cycle arrest.
Cell. 1995;
83(6):993-1000.
[PubMed: 8521522]
88. Overholtzer M, Rao PH, Favis R, et al. The presence of p53
mutations in human osteosarcomas correlates with high levels of
genomic instability. Proc Natl Acad Sci U S A. 2003;100(20):11547-11552.
89. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and
outcome in osteosarcoma: a prospective, multicenter study. J
Clin Oncol. 2005;23(7):1483-1490.
90. Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and
clinical outcome in osteosarcoma. Cancer. 2007;109(9):1870-1876.
91. Nevins JR. The Rb/E2F pathway and cancer. Hum
Mol Genet. 2001;10(7):699-703.
92. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the Rb/E2F
pathway in cell growth control. J Cell Physiol. 1997;173(2):233-236.
93. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-16.
94. Classon M, Harlow E. The retinoblastoma tumour suppressor
in development and cancer. Nat Rev Cancer. 2002;2(12):910-917.
95. Schmitt CA, Fridman JS, Yang M, et al. A senescence program
controlled by p53 and p16INK4a contributes to the outcome of cancer
therapy. Cell. 2002;109(3):335-346.
96. Lowe SW. Cancer therapy and p53. Curr Opin Oncol. 1995;7(6):547-553.
97. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the
efficacy of cancer therapy in vivo. Science. 1994;266(5186):807-810.
98. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in
bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967-976.
99. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from
cultured mesenchymal stem cells. Stem Cells. 2007;25(2):371-379.
100. Al-Romaih K, Bayani J, Vorobyova J, et al. Chromosomal
instability in osteosarcoma and its association with centrosome
abnormalities. Cancer Genet Cytogenet. 2003;144(2):91-99.
101. Johnson-Pais TL, Nellissery MJ, Ammerman DG, et al. Determination
of a minimal region of loss of heterozygosity on chromosome 18q21.33
in osteosarcoma. Int J Cancer. 2003;105(2):285-288.
102. Kruzelock RP, Murphy EC, Strong LC, Naylor SL, Hansen MF.
Localization of a novel tumor suppressor locus on human chromosome
3q important in osteosarcoma tumorigenesis. Cancer Res. 1997;57(1):106-109.
103. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks
MW, Weinberg RA. Creation of human tumour cells with defined genetic
elements. Nature. 1999;400(6743):464-468.
104. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of
insulin-like growth factor receptor, IGF-1, and IGF-2 in primary
and metastatic osteosarcoma. J Surg Oncol. 1998;69(1):21-27.
105. Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree
of intratumoural microvessel density and VEGF expression have prognostic
significance in osteosarcoma? Oncol Rep. 2006;16
(1):17-23.
106. Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch
D. Evaluation of the predictive value of Her-2/neu gene
expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab
Invest. 2004;84(1):113-121.
107. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein,
HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous
lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100(9):1936-1942.
108. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2
correlates with survival in osteosarcoma. J Clin Oncol. 1999;17(9):2781-2788.
109.Hoang BH, Dyke JP, Koutcher JA, et al. VEGF
expression in osteosarcoma correlates with vascular permeability
by dynamic MRI. Clin Orthop Relat Res. 2004(426):32-38.
110.Hughes DP, Thomas DG, Giordano TJ, Baker LH,
McDonagh KT. Cell surface expression of epidermal growth factor
receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer
Res. 2004;64(6):2047-2053.
111. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH.
Essential erbB family phosphorylation in osteosarcoma as a target
for CI-1033 inhibition. Pediatr Blood Cancer. 2006;46
(5):614-623.
112. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression
and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005;28(8):755-760.
113. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic
analysis of HER-2/neu immunoexpression among various histologic
subtypes and grades of osteosarcoma. Mod Pathol. 2001;14
(12):1277-1283.
114. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes
to the malignant phenotype in human and canine osteosarcoma. J
Cell Biochem. 2004;92(1):77-91.
115. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression
in the primary site and the metastatic site of human osteosarcoma:
analysis within a group of patients, all of whom developed lung
metastasis. Mod Pathol. 2006;19(5):738-745.
116. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is
correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77(1):
71-78.
117. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu
and p53 in osteosarcoma: an immunohistochemical and fluorescence
in situ hybridization analysis. Cancer Invest. 2004;22(1):16-24.
118. Willmore-Payne C, Holden JA, Zhou H, et al. Evaluation
of Her-2/neu gene status in osteosarcoma by fluorescence
in situ hybridization and multiplex and monoplex polymerase chain
reactions. Arch Pathol Lab Med. 2006;130(5):691-698.
119. Yalcin B, Gedikoglu G, Kutluk T, Varan A, Akyuz C, Buyukpamukcu
M. C-erbB-2 expression and prognostic significance in osteosarcoma. Pediatr
Blood Cancer. 2008;51(2):222-227.
120. Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid
hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int
J Cancer. 2007;121(5):943-954.
121. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM,
Goldsby RE. Her-2/neu expression in osteosarcoma increases
risk of lung metastasis and can be associated with gene amplification.
J Pediatr Hematol Oncol. 2003;25(1):27-32.
122. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF
receptor in proliferation and invasive behavior of osteosarcoma. FASEB
J. 2003;17(9):1162-1164.
123. Bostedt KT, Schmid C, Ghirlanda-Keller C, Olie
R, Winterhalter KH, Zapf J. Insulin-like growth factor (IGF) I down-regulates
type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549
non-small-cell lung cancer and Saos-2/B-10 osteoblastic
osteosarcoma cells. Exp Cell Res. 2001;271(2):368-377.
124. Kappel CC, Velez-Yanguas MC, Hirschfeld S,
Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like
growth factor I for in vitro growth. Cancer Res. 1994;54(10):2803-2807.
125. Pollak M, Sem AW, Richard M, Tetenes E, Bell
R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J
Natl Cancer Inst. 1992;84(12):966-971.
126. Pollak MN, Polychronakos C, Richard M. Insulinlike
growth factor I: a potent mitogen for human osteogenic sarcoma. J
Natl Cancer Inst. 1990;82(4):301-305.
127. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor
in cancer biology. Int J Cancer. 2003;107(6):873-877.
128. Scotlandi K, Manara MC, Nicoletti G, et al.
Antitumor activity of the insulin-like growth factor-I receptor
kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer
Res. 2005;65(9): 3868-3876.
129. Rong S, Oskarsson M, Faletto D, et al. Tumorigenesis
induced by coexpression of human hepatocyte growth factor and the
human met protooncogene leads to high levels of expression of the
ligand and receptor. Cell Growth Differ. 1993;4(7):563-569.
130. Scotlandi K, Baldini N, Oliviero M, et al.
Expression of Met/hepatocyte growth factor receptor gene
and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996;149(4):1209-1219.
131. Ferracini R, Di Renzo MF, Scotlandi K, et al.
The Met/HGF receptor is over-expressed in human osteosarcomas
and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995;10(4):739-749.
132. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi
M. Comparison of histological changes and changes in nm23 and c-MET
expression between primary and metastatic sites in osteosarcoma:
a clinicopathologic and immunohistochemical study. Hum Pathol. 2000;31(6):709-716.
133. McGary EC, Weber K, Mills L, et al. Inhibition
of platelet-derived growth factor-mediated proliferation of osteosarcoma
cells by the novel tyrosine kinase inhibitor STI571.
Clin
Cancer Res. 2002; 8(11):3584-3591.
[PubMed: 12429650]
134. Kawai T, Hiroi S, Torikata C. Expression in
lung carcinomas of platelet-derived growth factor and its receptors. Lab
Invest. 1997;77(5):431-436.
135. Nakanishi K, Hiroi S, Kawai T, Torikata C.
Expression of platelet-derived growth-factor B-chain mRNA and tumor
angiogenesis in invasive transitional cell carcinoma of the upper
urinary tract. Mod Pathol. 1997;10(4):341-347.
136. Sulzbacher I, Birner P, Trieb K, Muhlbauer
M, Lang S, Chott A. Platelet-derived growth factor-alpha receptor
expression supports the growth of conventional chondrosarcoma and
is associated with adverse outcome. Am J Surg Pathol. 2001;25
(12):1520-1527.
137. Sulzbacher I, Traxler M, Mosberger I, Lang
S, Chott A. Platelet-derived growth factor-AA and -alpha receptor
expression suggests an autocrine and/or paracrine loop
in osteosarcoma. Mod Pathol. 2000;13(6):632-637.
138. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived
growth factor receptor inhibition and chemotherapy for castration-resistant
prostate cancer with bone metastases. Clin Cancer Res. 2007;13(19):5816-5824.
139. Singh PK, Wen Y, Swanson BJ, et al. Platelet-derived growth
factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness
in pancreatic adenocarcinoma cells. Cancer Res. 2007;67(11):5201-5210.
140. Li T, Wen H, Brayton C, et al. Epidermal growth
factor receptor and notch pathways participate in the tumor suppressor
function of gamma-secretase. J Biol Chem. 2007;282(44):32264-32273.
141. Wen YH, Koeppen H, Garcia R, et al. Epidermal
growth factor receptor in osteosarcoma: expression and mutational
analysis. Hum Pathol. 2007;38(8):1184-1191.
142. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived
growth factor receptor as a prognostic marker and a therapeutic
target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112
(10):2119-2129.
143. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression
is correlated with increased survival of patients with osteosarcoma. Cancer. 2002;94(5):
1397-1404.
144. Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki
S, Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions
in osteosarcoma. Oncology. 2001;60(4):361-366.
145. Flint AF, U’Ren L, Legare ME, Withrow
SJ, Dernell W, Hanneman WH. Overexpression of the erbB-2 proto-oncogene
in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004;41(3):
291-296.
146. Merimsky O, Kollender Y, Issakov J, et al.
Induction chemotherapy for bone sarcoma in adults: correlation of
results with erbB-4 expression. Oncol Rep. 2003;10(5):1593-1599.
147. Rakesh Kumar V, Gupta N, Kakkar N, Sharma SC.
Prognostic and predictive value of c-erbB2 overexpression in osteogenic
sarcoma. J Cancer Res Ther. 2006;2(1):20-23.
148. Valabrega G, Fagioli F, Corso S, et al. ErbB2
and bone sialoprotein as markers for metastatic osteosarcoma cells. Br
J Cancer. 2003;88(3):396-400.
149. Yalcin B, Gedikoglu G, Kutluk T, et al. C-erbB-2
expression and prognostic significance in osteosarcoma. Pediatr
Blood Cancer. 2008;51(2):222-227.
150. Lee WI, Bacchni P, Bertoni F, Maeng YH, Park
YK. Quantitative assessment of HER2/neu expression by real-time
PCR and fluorescent in situ hybridization analysis in low-grade
osteosarcoma. Oncol Rep. 2004;12(1):125-128.
151. Scotlandi K, Manara MC, Hattinger CM, et al.
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma
and Ewing’s sarcoma. Eur J Cancer. 2005;41(9):1349-1361.
152. Somers GR, Ho M, Zielenska M, Squire JA, Thorner
PS. HER2 amplification and overexpression is not present in pediatric
osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 2005;8(5):
525-532.
153. Thomas DG, Giordano TJ, Sanders D, Biermann
JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma
and skeletal Ewing’s sarcoma. Clin Cancer Res. 2002;8(3):788-793.
154. Houghton PJ, Huang S. mTOR as a target for
cancer therapy.
Curr Top Microbiol Immunol. 2004;279:339-359.
[PubMed: 14560967]
155. Huang S, Houghton PJ. Targeting mTOR signaling
for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371-377.
156. Kurmasheva RT, Houghton PJ. IGF-I mediated
survival pathways in normal and malignant cells. Biochim
Biophys Acta. 2006;1766(1):1-22.
157. Kurmasheva RT, Huang S, Houghton PJ. Predicted
mechanisms of resistance to mTOR inhibitors. Br J Cancer. 2006;95(8):955-960.
158. Cowley S, Paterson H, Kemp P, Marshall CJ.
Activation of MAP kinase is necessary and sufficient for PC12 differentiation
and for transformation of NIH 3T3 cells. Cell. 1994;77(6):841-852.
159. Mansour SJ, Matten WT, Hermann AS, et al. Transformation
of mammalian cells by constitutively active MAP kinase kinase.
Science. 1994;
265(5174):966-970.
[PubMed: 8052857]
160. Davies H, Bignell GR, Cox C, et al. Mutations
of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
161. Salasznyk RM, Klees RF, Hughlock MK, Plopper
GE. ERK signaling pathways regulate the osteogenic differentiation
of human mesenchymal stem cells on collagen I and vitronectin. Cell
Commun Adhes. 2004;11(5-6):137-153.
162. Thimmaiah KN, Easton J, Huang S, et al. Insulin-like growth
factor I-mediated protection from rapamycin-induced apoptosis is
independent of Ras-Erk1-Erk2 and phosphatidylinositol 3-kinase-Akt
signaling pathways.
Cancer Res. 2003; 63(2):364-374.
[PubMed: 12543789]
163. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman
LJ. Ezrin mediates growth and survival in Ewing’s sarcoma
through the AKT/mTOR, but not the MAPK, signaling pathway. Clin
Exp Metastasis. 2006;23(3-4):227-236.
164. Yu W, Chen Z, Zhang J, et al. Critical role of phosphoinositide
3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol
Cell Biochem. 2008;310(1-2):11-18.
165. Bjornsti MA, Houghton PJ. The TOR pathway: a target for
cancer therapy. Nat Rev Cancer. 2004;4(5):335-348.
166. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25(48):6436-6446.
167. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos
in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology. 1998;55(6):556-563.
168. Ikeda S, Sumii H, Akiyama K, et al. Amplification of both
c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn
J Cancer Res. 1989;80(1):6-9.
169. Kochevar DT, Kochevar J, Garrett L. Low level amplification
of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer
Lett. 1990;53(2-3):213-222.
170. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos
AG. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn
Mol Pathol. 1993;2(3):163-167.
171. Finkel MP, Jinkins PB, Tolle J, Biskis BO. Serial radiography
of virus-induced osteosarcomas in mice. Radiology. 1966;87(2):333-339.
172. Miller AD, Curran T, Verma IM. c-fos protein can induce
cellular transformation: a novel mechanism of activation of a cellular
oncogene. Cell. 1984;36(1):51-60.
173. Curran T, MacConnell WP, van Straaten F, Verma IM. Structure
of the FBJ murine osteosarcoma virus genome: molecular cloning of
its associated helper virus and the cellular homolog of the v-fos
gene from mouse and human cells. Mol Cell Biol. 1983;3(5):914-921.
174. Curran T, Verma IM. FBR murine osteosarcoma virus. I. Molecular
analysis and characterization of a 75,000-Da gag-fos fusion product. Virology. 1984;135(1):218-228.
175. Franchi A, Calzolari A, Zampi G. Immunohistochemical detection
of c-fos and c-jun expression in osseous and cartilaginous tumours
of the skeleton. Virchows Arch. 1998;432(6):515-519.
176. Kakar S, Mihalov M, Chachlani NA, Ghosh L, Johnstone H.
Correlation of c-fos, p53, and PCNA expression with treatment outcome
in osteosarcoma. J Surg Oncol. 2000;73(2):125-126.
177. Bayani J, Zielenska M, Pandita A, et al. Spectral karyotyping
identifies recurrent complex rearrangements of chromosomes 8, 17,
and 20 in osteosarcomas. Genes Chromosomes Cancer. 2003;36(1):7-16.
178. Squire JA, Pei J, Marrano P, et al. High-resolution mapping
of amplifications and deletions in pediatric osteosarcoma by use
of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer. 2003;38(3):215-225.
179. Zielenska M, Marrano P, Thorner P, et al. High-resolution
cDNA microarray CGH mapping of genomic imbalances in osteosarcoma
using formalin-fixed paraffin-embedded tissue. Cytogenet
Genome Res. 2004;107(1-2):77-82.
180. Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase
hypothesis of aging and cancer. Nat Biotechnol. 1996;14(7):836-839.
181. Shay JW, Wright WE. Telomerase therapeutics for cancer:
challenges and new directions. Nat Rev Drug Discov. 2006;5(7):577-584.
182. Aue G, Muralidhar B, Schwartz HS, Butler MG. Telomerase
activity in skeletal sarcomas. Ann Surg Oncol. 1998;5(7):627-634.
183. Nakashima H, Nishida Y, Sugiura H, et al. Telomerase, p53
and PCNA activity in osteosarcoma. Eur J Surg Oncol. 2003;29(7):564-567.
184. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB,
Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J
Clin Oncol. 2004;22(18):3790-3797.
185. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere
maintenance mechanism as a favorable prognostic factor in patients
with osteosarcoma. Cancer Res. 2003;63(8):1759-1763.
186. Deshpande A, Hinds PW. The retinoblastoma protein in osteoblast
differentiation and osteosarcoma. Curr Mol Med. 2006;6(7):809-817.
187. Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic
differentiation: a new perspective on oncogenesis.
Clin
Orthop Relat Res. 2007;454: 237-246.
[PubMed: 17075380]
188. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma
development and stem cell differentiation. Clin Orthop Relat
Res. 2008;466(9): 2114-2130.
189. Kloen P, Gebhardt MC, Perez-Atayde A, et al. Expression
of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas:
TGF-beta3 is related to disease progression. Cancer. 1997;80(12):2230-2239.
190. Guo W, Gorlick R, Ladanyi M, et al. Expression of bone
morphogenetic proteins and receptors in sarcomas. Clin Orthop
Relat Res. 1999 (365):175-183.
191. Ohta S, Hiraki Y, Shigeno C, et al. Bone morphogenetic
proteins (BMP-2 and BMP-3) induce the late phase expression of the
proto-oncogene c-fos in murine osteoblastic MC3T3-E1 cells. FEBS
Lett. 1992;314(3):356-360.
192. Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits
invasion and motility of Saos-2 osteosarcoma cells by modulating
the Wnt-beta-catenin pathway. Cancer Res. 2004;64(8):2734-2739.
193. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related
protein 5 (LRP5) as a novel marker for disease progression in high-grade
osteosarcoma. Int J Cancer. 2004;109 (1):106-111.
194. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes
proliferation and suppresses osteogenic differentiation of adult
human mesenchymal stem cells. J Cell Biochem. 2004;93(6):1210-1230.
195. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837-1851.
196. Chen K, Fallen S, Abaan HO, et al. Wnt10b induces chemotaxis
of osteosarcoma and correlates with reduced survival. Pediatr
Blood Cancer. 2008;51(3):349-355.
197. O’Keefe RJ, Guise TA. Molecular mechanisms of
bone metastasis and therapeutic implications. Clin Orthop
Relat Res. 2003(415 Suppl): S100-S104.
198. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The
seed and soil hypothesis: vascularisation and brain metastases. Lancet
Oncol. 2002;3(1): 53-57.
199. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer
TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived
factor 1 (SDF-1). J Exp Med. 1996;184(3):1101-1109.
200. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression
levels of CXCR4 correlate with metastatic behavior and outcome in
patients with osteosarcoma. Clin Cancer Res. 2005;11(7):2561-2567.
201. Miura K, Uniyal S, Leabu M, et al. Chemokine receptor CXCR4-beta1
integrin axis mediates tumorigenesis of osteosarcoma HOS cells. Biochem
Cell Biol. 2005;83(1):36-48.
202. Perissinotto E, Cavalloni G, Leone F, et al. Involvement
of chemokine receptor 4/stromal cell-derived factor 1 system
during osteosarcoma tumor progression. Clin Cancer Res. 2005;11(2
Pt 1):490-497.
203. von Luettichau I, Nathrath M, Burdach S, Huss R, Segerer
S, Nelson PJ. Mononuclear infiltrates in osteosarcoma and chemokine
receptor expression. Clin Cancer Res. 2006;12(17):5253-5254;
author reply 5254.
204. von Luettichau I, Segerer S, Wechselberger A, et al. A
complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC
Cancer. 2008;8:23.
205. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12
chemokine pathway reduces the development of murine pulmonary metastases. Clin
Exp Metastasis. 2008;25(3):201-211.
206. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton
linker ezrin is necessary for osteosarcoma metastasis. Nat
Med. 2004;10(2):182-186.
207. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi
K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1
is correlated with poor prognosis in patients with osteosarcoma. Int
J Oncol. 2006;28(1):33-42.
208. Heikkila P, Teronen O, Hirn MY, et al. Inhibition of matrix
metalloproteinase-14 in osteosarcoma cells by clodronate. J
Surg Res. 2003;111 (1):45-52.
209. Kido A, Tsutsumi M, Iki K, et al. Inhibition of spontaneous
rat osteosarcoma lung metastasis by 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc
arbostyril, a novel matrix metalloproteinase inhibitor. Jpn
J Cancer Res. 1999;90(3):333-341.
210. Himelstein BP, Asada N, Carlton MR, Collins MH. Matrix
metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med
Pediatr Oncol. 1998;31(6):471-474.
211. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis
EM. Exploratory analysis of Fas gene polymorphisms in pediatric
osteosarcoma patients. J Pediatr Hematol Oncol. 2007;29(12):
815-821.
212. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman
ES. Fas-negative osteosarcoma tumor cells are selected during metastasis
to the lungs: the role of the Fas pathway in the metastatic process
of osteosarcoma. Mol Cancer Res. 2007;5(10):991-999.
213. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in
lung metastasis from osteosarcoma patients. J Pediatr Hematol
Oncol. 2005;27 (11): 611-615.
214. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression
inversely correlates with metastatic potential in osteosarcoma cells. Oncol
Rep. 2002;9(4):823-827.
215. Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH,
Gorlick R. Hypoxia markers in human osteosarcoma: an exploratory
study. Clin Orthop Relat Res. 2008;466(9):2052-2059.
216. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression
of P-glycoprotein in high-grade osteosarcomas in relation to clinical
outcome. N Engl J Med. 1995;333(21):1380-1385.
217. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein
expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J
Orthop Res. 1999;17(5):629-632.
218. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein
expression: critical determinant in the response to osteosarcoma
chemotherapy. J Natl Cancer Inst. 1997;89(22):1706-1715.
219. Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein
levels predict poor outcome in patients with osteosarcoma. Clin
Orthop Relat Res. 2000(373):11-17.
220. Kumta SM, Zhu QS, Lee KM, Griffith J, Chow LT, Leung PC.
Clinical significance of P-glycoprotein immunohistochemistry and
doxorubicin binding assay in patients with osteosarcoma. Int
Orthop. 2001;25(5):279-282.
221. Pakos EE, Ioannidis JP. The association of P-glycoprotein
with response to chemotherapy and clinical outcome in patients with
osteosarcoma. A meta-analysis. Cancer. 2003;98(3):581-589.
222. Posl M, Amling M, Grahl K, et al. P-glycoprotein expression
in high grade central osteosarcoma and normal bone cells. An immunohistochemical
study. Gen Diagn Pathol. 1997;142(5-6):317-325.
223. Scotlandi K, Manara MC, Serra M, et al. The expression
of P-glycoprotein is causally related to a less aggressive phenotype
in human osteosarcoma cells. Oncogene. 1999;18(3):739-746.
224. Serra M, Maurici D, Scotlandi K, et al. Relationship between
P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int
J Oncol. 1999;14(2):301-307.
225. Serra M, Picci P, Ferrari S, Bacci G. Prognostic value
of P-glycoprotein in high-grade osteosarcoma. J Clin Oncol. 2007;25(30):4858-4860;
author reply 4860-4861.
226. Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of
the multidrug resistance gene in osteosarcoma: a pilot study. J
Orthop Res. 1993;11(3):396-403.
227. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression
and outcome in osteosarcoma: a prospective, multicenter study. J
Clin Oncol. 2000;18(14):2685-2694.
228. Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance
in osteogenic sarcoma: INT0133 from the Children’s Oncology
Group. J Clin Oncol. 2007;25(15):2057-2062.
229. Trammell RA, Johnson CB, Barker JR, Bell RS, Allan DG.
Multidrug resistance-1 gene expression does not increase during
tumor progression in the MGH-OGS murine osteosarcoma tumor model. J
Orthop Res. 2000;18(3):449-455.
230. Serra M, Pasello M, Manara MC, et al. May P-glycoprotein
status be used to stratify high-grade osteosarcoma patients? Results
from the Italian/Scandinavian Sarcoma Group 1 treatment
protocol. Int J Oncol. 2006;29(6):1459-1468.
231. Guo W, Healey JH, Meyers PA, et al. Mechanisms of
methotrexate
resistance in osteosarcoma.
Clin Cancer Res. 1999;5(3):621-627.
232. Yang R, Kolb EA, Qin J, et al. The folate receptor alpha
is frequently overexpressed in osteosarcoma samples and plays a
role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin
Cancer Res. 2007;13(9):2557-2567.
233. Yang R, Li WW, Hoang BH, et al. Quantitative correlation
between promoter methylation and messenger RNA levels of the reduced
folate carrier.
BMC Cancer. 2008;8(1):124.
[PubMed: 18452618]
234. Yang R, Qin J, Hoang BH, Healey JH, Gorlick R. Polymorphisms
and methylation of the reduced folate carrier in osteosarcoma. Clin
Orthop Relat Res. 2008;466(9):2046-2051.
235. Yang R, Sowers R, Mazza B, et al. Sequence alterations
in the reduced folate carrier are observed in osteosarcoma tumor
samples. Clin Cancer Res. 2003;9(2):837-844.
236. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee
D. Resistance mechanisms to
methotrexate in tumors.
Oncologist. 1996;1(4):223-226.
237. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D,
Bertino JR. Intrinsic and acquired resistance to
methotrexate in
acute leukemia.
N Engl J Med. 1996;335(14):1041-1048.
238. Scionti I, Michelacci F, Pasello M, et al. Clinical impact
of the
methotrexate resistance-associated genes C-MYC and dihydrofolate
reductase (DHFR) in high-grade osteosarcoma.
Ann Oncol. 2008;19(8):1500-1508.
239. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis
of dihydrofolate reductase and reduced folate carrier gene status
in relation to
methotrexate resistance in osteosarcoma cells.
Ann
Oncol. 2004;15(1):151-160.
240. Bielack S, Carrle D, Jost L. Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann
Oncol. 2008;19 Suppl 2:ii94-96.
241. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma:
where do we go from here? Pediatric Drugs. 2008;10(5):315-327.
242. Guerra RB, Tostes MD, da Costa Miranda L, et al. Comparative
analysis between osteosarcoma and Ewing’s sarcoma: evaluation
of the time from onset of signs and symptoms until diagnosis. Clinics. 2006;61(2):99-106.
243. Sneppen O, Hansen LM. Presenting symptoms and treatment
delay in osteosarcoma and Ewing’s sarcoma. Acta
Radiol Oncol. 1984;23(2-3):159-162.
244. Widhe B, Widhe T. Initial symptoms and clinical features
in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000;82(5):667-674.
245. Bielack SS, Kempf-Bielack B, Delling G, et
al. Prognostic factors in high-grade osteosarcoma of the extremities
or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-790.
246. Pollock BH, Krischer JP, Vietti TJ. Interval
between symptom onset and diagnosis of pediatric solid tumors. J
Pediatr. 1991;119(5):725-732.
247. Bloem JL, Taminiau AH, Eulderink F, Hermans
J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging,
scintigraphy, angiography, and CT correlated with pathologic examination. Radiology. 1988;169(3):805-810.
248. Gillespy T, 3rd, Manfrini M, Ruggieri P, Spanier
SS, Pettersson H, Springfield DS. Staging of intraosseous extent
of osteosarcoma: correlation of preoperative CT and MR imaging with
pathologic macroslides. Radiology. 1988;167(3):
765-767.
249. Panicek DM, Gatsonis C, Rosenthal DI, et al.
CT and MR imaging in the local staging of primary malignant musculoskeletal
neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202(1):237-246.
250. Saifuddin A. The accuracy of imaging in the
local staging of appendicular osteosarcoma. Skeletal Radiol. 2002;31(4):191-201.
251. Yao L, Nelson SD, Seeger LL, Eckardt JJ, Eilber
FR. Primary musculoskeletal neoplasms: effectiveness of core-needle
biopsy.
Radiology. 1999; 212(3):682-686.
[PubMed: 10478232]
252. Ahrar K, Himmerich JU, Herzog CE, et al. Percutaneous
ultrasound-guided biopsy in the definitive diagnosis of osteosarcoma. J
Vasc Interv Radiol. 2004;15(11):1329-1333.
253. Davies NM, Livesley PJ, Cannon SR. Recurrence
of an osteosarcoma in a needle biopsy track. J Bone Joint
Surg Br. 1993;75(6):977-978.
254. Iemsawatdikul K, Gooding CA, Twomey EL, et
al. Seeding of osteosarcoma in the biopsy tract of a patient with
multifocal osteosarcoma. Pediatr Radiol. 2005;35(7):717-721.
255. Peabody TD, Simon MA. Making the diagnosis:
keys to a successful biopsy in children with bone and soft-tissue
tumors. Orthop Clin North Am. 1996;27(3):453-459.
256. Mankin HJ, Mankin CJ, Simon MA. The hazards
of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J
Bone Joint Surg Am. 1996;78(5):656-663.
257. Abdelnoor J. Osteosarcoma clinical and laboratory
evaluation with staging.
J Med Liban. 1992; 40(1):36-38.
[PubMed: 1339872]
258. Meyer JS, Nadel HR, Marina N, et al. Imaging
guidelines for children with Ewing sarcoma and osteosarcoma: A report
from the Children’s Oncology Group Bone Tumor Committee.
Pediatr
Blood Cancer. 2008;51:163–170.
[PubMed: 18454470]
259. Picci P, Vanel D, Briccoli A, et al. Computed tomography
of pulmonary metastases from osteosarcoma: the less poor technique.
A study of 51 patients with histological correlation. Ann
Oncol. 2001;12(11):1601-1604.
260. Meyers PA. Malignant bone tumors in children: osteosarcoma. Hematol
Oncol Clin North Am. 1987;1(4):655-665.
261. Meyers PA, Heller G, Healey J, et al. Chemotherapy for
nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J
Clin Oncol. 1992;10(1):5-15.
262. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma
with clinically detectable metastasis at initial presentation. J
Clin Oncol. 1993;11(3):449-453.
263. McKillop JH, Etcubanas E, Goris ML. The indications
for and limitations of bone scintigraphy in osteogenic sarcoma:
a review of 55 patients. Cancer. 1981;48(5):1133-1138.
264. Kager L, Zoubek A, Kastner U, et al. Skip metastases in
osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J
Clin Oncol. 2006;24(10):1535-1541.
265. Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis
of osteosarcoma skip metastases.
Clin Orthop Relat Res. 2004;426:92-96.
[PubMed: 15346057]
266. Bhagia SM, Grimer RJ, Davies AM, Mangham DC. Scintigraphically
negative skip metastasis in osteosarcoma. Eur Radiol. 1997;7(9):1446-1448.
267. Enneking WF, Kagan A. “Skip” metastases
in osteosarcoma. Cancer. 1975;36(6):2192-2205.
268. Aizawa T, Okada K, Abe E, Tsuchida S, Shimada
Y, Itoi E. Multicentric osteosarcoma with long-term survival. Skeletal
Radiol. 2004;33(1):41-45.
269. Cabitza P, Mapelli S. Multicentric osteosarcoma.
Presentation of a case and review of the literature. Ital
J Orthop Traumatol. 1981;7(2):255-260.
270. Daffner RH, Kennedy SL, Fox KR, Crowley JJ,
Sauser DD, Cooperstein LA. Synchronous multicentric osteosarcoma:
the case for metastases. Skeletal Radiol. 1997;26(10):569-578.
271. Brenner W, Bohuslavizki KH, Eary JF. PET imaging
of osteosarcoma. J Nucl Med. 2003;44(6):930-942.
272. Franzius C, Bielack S, Flege S, Sciuk J, Jurgens
H, Schober O. Prognostic significance of (18)F-FDG and (99m)Tc-methylene
diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43
(8):1012-1017.
273. Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC,
Hsu YC. Comparison between F-18-FDG positron emission tomography
and histology for the assessment of tumor necrosis rates in primary
osteosarcoma. J Chin Med Assoc. 2006;69 (8):372-376.
274. Nair N, Ali A, Green AA, et al. Response of
osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin
Positron Imaging. 2000;3 (2):79-83.
275. Sato J, Yanagawa T, Dobashi Y, Yamaji T, Takagishi K, Watanabe
H. Prognostic significance of 18F-FDG uptake in primary osteosarcoma
after but not before chemotherapy: a possible association with autocrine
motility factor/phosphoglucose isomerase expression. Clin
Exp Metastasis. 2008;25(4):427-435.
276. Gorlick R. Osteosarcoma: clinical practice
and the expanding role of biology. J Musculoskelet Neuronal
Interact. 2002;2(6):549-551.
277. Enneking WF, Spanier SS, Goodman MA. A system
for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 1980;Nov-Dec(153):106-120.
278. Glasser DB, Lane JM, Huvos AG, Marcove RC,
Rosen G. Survival, prognosis, and therapeutic response in osteogenic
sarcoma. The Memorial Hospital experience. Cancer. 1992;69(3):698-708.
279. Juergens H, Kosloff C, Nirenberg A, Mehta BM,
Huvos AG, Rosen G. Prognostic factors in the response of primary
osteogenic sarcoma to preoperative chemotherapy (high-dose
methotrexate
with citrovorum factor).
Natl Cancer Inst Monogr. 1981(56):221-226.
280. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli
A, Picci P. Prognostic factors for osteosarcoma of the extremity
treated with neoadjuvant chemotherapy: 15-year experience in 789
patients treated at a single institution. Cancer. 2006;106(5):1154-1161.
281. Bacci G, Ferrari S, Sangiorgi L, et al. Prognostic
significance of serum lactate dehydrogenase in patients with osteosarcoma
of the extremities. J Chemother. 1994;6(3):204-210.
282. Bacci G, Longhi A, Ferrari S, et al. Prognostic
significance of serum lactate dehydrogenase in osteosarcoma of the
extremity: experience at Rizzoli on 1421 patients treated over the
last 30 years. Tumori. 2004;90(5):478-484.
283. Bacci G, Longhi A, Ferrari S, et al. Prognostic
significance of serum alkaline phosphatase in osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: recent experience
at Rizzoli Institute. Oncol Rep. 2002;9(1):171-175.
284. Bacci G, Picci P, Orlandi M, et al. Prognostic
value of serum alkaline phosphatase in osteosarcoma. Tumori. 1987;73(4):331-336.
285. Rosen G, Murphy ML, Huvos AG, Gutierrez M,
Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone
replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37(1):
1-11.
286. Huvos AG, Rosen G, Marcove RC. Primary osteogenic
sarcoma: pathologic aspects in 20 patients after treatment with
chemotherapy en bloc resection, and prosthetic bone replacement. Arch
Pathol Lab Med. 1977;101(1):14-18.
287. Meyers PA, Gorlick R, Heller G, et al. Intensification
of preoperative chemotherapy for osteogenic sarcoma: results of
the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16(7):2452-2458.
288. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant
chemotherapy for extremity osteosarcoma—preliminary results
of the Rizzoli’s 4th study. Acta Oncol. 1998;37(1):41-48.
289. Bacci G, Picci P, Ferrari S, Sangiorgi L, Zanone
A, Brach del Prever A. Primary chemotherapy and delayed surgery
for non-metastatic telangiectatic osteosarcoma of the extremities.
Results in 28 patients. Eur J Cancer. 1994;30A(5):620-626.
290. Bacci G, Picci P, Gherlinzoni F, et al. Neoadjuvant
chemotherapy for high grade osteosarcoma of the extremities: is
a good response to preoperative treatment an indication to reduce
postoperative chemotherapy? Chemioterapia. 1986;5(2):
140-143.
291. Bacci G, Picci P, Ruggieri P, et al. Primary
chemotherapy and delayed surgery (neoadjuvant chemotherapy) for
osteosarcoma of the extremities. The Istituto Rizzoli Experience
in 127 patients treated preoperatively with intravenous
methotrexate
(high versus moderate doses) and intraarterial cisplatin.
Cancer. 1990;65(11):2539-2553.
292. Ferrari S, Avella M, Briccoli A, et al. Primary
chemotherapy and delayed surgery for osteosarcoma of the extremities
with synchronous metastases. Ann Oncol. 1992;3
Suppl 2:S39-41.
293. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant
chemotherapy with high-dose Ifosfamide, high-dose
methotrexate,
cisplatin, and doxorubicin for patients with localized osteosarcoma
of the extremity: a joint study by the Italian and Scandinavian
Sarcoma Groups.
J Clin Oncol. 2005;23(34):8845-8852.
294. Gorlick R, Meyers PA. Osteosarcoma necrosis
following chemotherapy: innate biology versus treatment-specific. J
Pediatr Hematol Oncol. 2003;25(11):840-841.
295. Goorin AM, Delorey MJ, Lack EE, et al. Prognostic
significance of complete surgical resection of pulmonary metastases
in patients with osteogenic sarcoma: analysis of 32 patients. J
Clin Oncol. 1984;2(5):425-431.
296. Goorin AM, Harris MB, Bernstein M, et al. Phase
II/III trial of etoposide and high-dose ifosfamide in newly
diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J
Clin Oncol. 2002;20(2):426-433.
297. Kager L, Zoubek A, Potschger U, et al. Primary
metastatic osteosarcoma: presentation and outcome of patients treated
on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J
Clin Oncol. 2003;21(10):2011-2018.
298. Fletcher CDM, Unni KK, Mertens F, World Health
Organization, International Agency for Research on Cancer. Pathology
and Genetics of Tumours of Soft Tissue and Bone. Lyon:
IARC Press; 2002.
299. Farr GH, Huvos AG, Marcove RC, Higinbotham
NL, Foote FW, Jr. Telangiectatic osteogenic sarcoma. A review of
twenty-eight cases. Cancer. 1974;34(4):1150-1158.
300. Rosen G, Huvos AG, Marcove R, Nirenberg A.
Telangiectatic osteogenic sarcoma. Improved survival with combination
chemotherapy. Clin Orthop Relat Res. 1986(207):164-173.
301. Matsuno T, Unni KK, McLeod RA, Dahlin DC. Telangiectatic
osteogenic sarcoma.
Cancer. 1976; 38(6):2538-2547.
[PubMed: 1069603]
302. Nakajima H, Sim FH, Bond JR, Unni KK. Small
cell osteosarcoma of bone. Review of 72 cases. Cancer. 1997;79(11):2095-2106.
303. Devaney K, Vinh TN, Sweet DE. Small cell osteosarcoma
of bone: an immunohistochemical study with differential diagnostic
considerations. Hum Pathol. 1993;24(11):1211-1225.
304. Ayala AG, Ro JY, Raymond AK, et al. Small cell
osteosarcoma. A clinicopathologic study of 27 cases. Cancer. 1989;64(10):2162-2173.
305. Dahlin DC, Coventry MB. Osteogenic sarcoma.
A study of six hundred cases. J Bone Joint Surg Am. 1967;49(1):101-110.
306. Friedman MA, Carter SK. The therapy of osteogenic
sarcoma: current status and thoughts for the future. J Surg
Oncol. 1972;4(5):482-510.
307. Goidanich IF, Battaglia L, Lenzi L, Silva E.
Osteogenic sarcoma. Analysis of factors influencing prognosis in
100 cases.
Clin Orthop Relat Res. 1966;48:209-222.
[PubMed: 5225593]
308. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter
RV. Osteogenic sarcoma under the age of twenty-one. A review of
one hundred and forty-five operative cases. J Bone Joint
Surg Am. 1970;52 (3):411-423.
309. McKenna RJ, Schwinn CP, Higinbotham NL. Osteogenic
sarcoma in children. CA Cancer J Clin. 1966;16(1):26-28.
310. Frei E, 3rd, Jaffe N, Gero M, Skipper H, Watts
H. Adjuvant chemotherapy of osteogenic sarcoma: progress and perspectives. J
Natl Cancer Inst. 1978;60(1):3-10.
311. Jaffe N. Recent advances in the chemotherapy
of metastatic osteogenic sarcoma. Cancer. 1972;30
(6):1627-1631.
312. Jaffe N, Frei E, 3rd, Traggis D, Bishop Y.
Adjuvant
methotrexate and citrovorum-factor treatment of osteogenic
sarcoma.
N Engl J Med. 1974;291 (19):994-997.
313. Jaffe N, Frei E, III, Traggis D, Watts H. Weekly
high-dose methotrexate-citrovorum factor in osteogenic sarcoma:
pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977;39(1):45-50.
314. Cores EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin
in disseminated osteosarcoma. JAMA. 1972;221(10):1132-1138.
315. Cortes EP, Holland JF, Wang JJ, et al. Amputation
and adriamycin in primary osteosarcoma. N Engl J Med. 1974;291(19):998-1000.
316. Pratt CB, Howarth C, Ransom JL, et al. High-dose
methotrexate used alone and in combination for measurable primary
or metastatic osteosarcoma.
Cancer Treat Rep. 1980;64(1):11-20.
317. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond
D. Phase II study of cis-dichlorodiammineplatinum(II) in childhood
osteosarcoma: Children’s Cancer Study Group Report. Cancer
Treat Rep. 1979;63(9-10):1621-1627.
318. Marti C, Kroner T, Remagen W, Berchtold W,
Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma.
Cancer
Treat Rep. 1985; 69(1):115-117.
[PubMed: 3855382]
319. Shamberger RC, Rosenberg SA, Seipp CA, Sherins
RJ. Effects of high-dose
methotrexate and vincristine on ovarian
and testicular functions in patients undergoing postoperative adjuvant
treatment of osteosarcoma.
Cancer Treat Rep. 1981;65(9-10):739-746.
320. Gasparini M, Tondini C, Rottoli L, Roncoroni
I. Continuous cisplatin infusion in combination with vincristine
and high-dose
methotrexate for advanced osteogenic sarcoma.
Am
J Clin Oncol. 1987;10(2):152-155.
321. Jaffe N, Traggis D, Enriquez C. Evaluation
of a combination of
mitomycin C (NSC-26980), phenylalanine mustard
(NSC-14210), and vincristine (NSC-67574) in the treatment of osteogenic
sarcoma.
Cancer Chemother Rep. 1971;55 (2):189-191.
322. Balis FM, Gillespie A, Belasco J, et al. Phase
II trial of sequential
methotrexate and 5-fluorouracil with leucovorin
in children with sarcomas.
Invest New Drugs. 1990;8(2):181-182.
323. Patel R, Newman EM, Villacorte DG, et al. Pharmacology
and phase I trial of high-dose oral leucovorin plus 5-fluorouracil
in children with refractory cancer: a report from the Children’s
Cancer Study Group. Cancer Res. 1991;51(18): 4871-4875.
324. Pratt CB, Meyer WH, Howlett N, et al. Phase
II study of 5-fluorouracil/leucovorin for pediatric patients
with malignant solid tumors. Cancer. 1994;74(9):2593-2598.
325. Sutow WW, Sullivan MP, Fernbach DJ, Cangir
A, George SL. Adjuvant chemotherapy in primary treatment of osteogenic
sarcoma. A Southwest Oncology Group study. Cancer. 1975;36(5):1598-1602.
326. Cortes EP, Holland JF, Glidewell O. Adjuvant
therapy of operable primary osteosarcoma-cancer and Leukemia Group
B experience.
Recent Results Cancer Res. 1978;68:16-24.
[PubMed: 288106]
327. Bacci G, Campanacci M, Picci P, Pagani P. Adjuvant multiple
drug chemotherapy for osteosarcoma of the extremity: a 6 year report. Tumori. 1979;65(5):587-600.
328. Ettinger LJ, Douglass HO, Jr., Higby DJ, et
al. Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum)
in primary osteosarcoma. Cancer. 1981;47(2):248-254.
329. Goorin AM, Frei E, 3rd, Abelson HT. Adjuvant
chemotherapy for osteosarcoma: a decade of experience. Surg
Clin North Am. 1981;61(6): 1379-1389.
330. Cantwell BM, Fennelly JJ, Jones MP. Adjuvant
systemic therapy after ablative surgery for limb osteosarcoma. Ir
J Med Sci. 1982;151(12):384-387.
331. Rosen G, Marcove RC, Huvos AG, et al. Primary
osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J
Cancer Res Clin Oncol. 1983;106 Suppl:55-67.
332. Carter SK. The dilemma of adjuvant chemotherapy
for osteogenic sarcoma. Cancer Clin Trials. 1980;3(1):29-36.
333. Lange B, Levine AS. Is it ethical not to conduct
a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer
Treat Rep. 1982;66(9):1699-1704.
334. Jaffe N, van Eys J, Gehan E. Response to: “Is
it ethical not to conduct a prospectively controlled trial of adjuvant
chemotherapy in osteosarcoma?” Cancer Treat Rep. 1983;67(7-8):743-745.
335. Carter SK. Adjuvant chemotherapy in osteogenic
sarcoma: the triumph that isn’t? J Clin Oncol. 1984;2(3):147-148.
336. Link MP, Goorin AM, Miser AW, et al. The effect
of adjuvant chemotherapy on relapse-free survival in patients with
osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600-1606.
337. Link MP, Goorin AM, Horowitz M, et al. Adjuvant
chemotherapy of high-grade osteosarcoma of the extremity. Updated
results of the Multi-Institutional Osteosarcoma Study. Clin
Orthop Relat Res. 1991;(270):8-14.
338. Rosen G, Caparros B, Huvos AG, et al. Preoperative
chemotherapy for osteogenic sarcoma: selection of postoperative
adjuvant chemotherapy based on the response of the primary tumor
to preoperative chemotherapy. Cancer. 1982;49(6):
1221-1230.
339. Bacci G, Ferrari S, Bertoni F, et al. Histologic
response of high-grade nonmetastatic osteosarcoma of the extremity
to chemotherapy. Clin Orthop Relat Res. 2001(386):186-196.
340. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic
osteosarcoma of the extremity: results of a neoadjuvant chemotherapy
protocol (IOR/OS-3) with high-dose
methotrexate, intraarterial
or intravenous cisplatin, doxorubicin, and salvage chemotherapy
based on histologic tumor response.
Tumori. 1999;85(6):458-464.
341. Provisor AJ, Ettinger LJ, Nachman JB, et al.
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative
and postoperative chemotherapy: a report from the Children’s
Cancer Group. J Clin Oncol. 1997;15(1):76-84.
342. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma
Group Osteosarcoma Study SSG VIII: prognostic factors for outcome
and the role of replacement salvage chemotherapy for poor histological
responders. Eur J Cancer. 2003;39(4): 488-494.
343. Winkler K, Beron G, Delling G, et al. Neoadjuvant
chemotherapy of osteosarcoma: results of a randomized cooperative
trial (COSS-82) with salvage chemotherapy based on histological
tumor response. J Clin Oncol. 1988;6(2):329-337.
344. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy
for osteogenic sarcoma: results of a Cooperative German/Austrian
study. J Clin Oncol. 1984;2(6):617-624.
345. Goorin AM, Schwartzentruber DJ, Devidas M,
et al. Presurgical chemotherapy compared with immediate surgery
and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric
Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574-1580.
346. Bacci G, Avella M, Brach Del Prevert A, et
al. Neoadjuvant chemotherapy for osteosarcoma of the extremities.
Good response of the primary tumor after preoperative chemotherapy
with high-dose
methotrexate followed by cisplatinum and adriamycin.
Preliminary results.
Chemioterapia. 1988;7(2):138-142.
347. Bacci G, Avella M, Picci P, et al. Neoadjuvant
chemotherapy for osteosarcoma of the extremities: the Rizzoli Institute
experience. Chir Organi Mov. 1990;75(1 Suppl):57-59.
348. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari
M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma
of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur
J Cancer. 2005;41(18):2836-2845.
349. Meyers PA, Heller G, Healey J. Retrospective
review of neoadjuvant chemotherapy for osteogenic sarcoma. J
Natl Cancer Inst. 5 1992;84 (3):202-204.
350. Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide,
and dactinomycin in metastatic osteosarcoma: lack of tumor regression
in previously treated patients. Cancer Treat Rep. 1987;71
(4):421-423.
351. Bacci G, Ferrari S, Forni C, et al. The effect
of intra-arterial versus intravenous cisplatinum in the neoadjuvant
treatment of osteosarcoma of the limbs: the experience at the Rizzoli
Institute. Chir Organi Mov. 1996;81(4):369-382.
352. Bacci G, Ruggieri P, Picci P, et al. Intra-arterial
versus intravenous cisplatinum (in addition to systemic Adriamycin
and high dose
methotrexate) in the neoadjuvant treatment of osteosarcoma
of the extremities. Results of a randomized study.
J Chemother. 1996;8(1):70-81.
353. Benjamin RS, Chawla SP, Carrasco CH, et al.
Preoperative chemotherapy for osteosarcoma with intravenous adriamycin
and intra-arterial cis-platinum. Ann Oncol. 1992;3
Suppl 2:S3-6.
354. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma:
intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum
II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51(3):402-407.
355. Jaffe N, Prudich J, Knapp J, et al. Treatment
of primary osteosarcoma with intra-arterial and intravenous high-dose
methotrexate.
J Clin Oncol. 1983;1(7):428-431.
356. Jaffe N, Robertson R, Ayala A, et al. Comparison
of intra-arterial cis-diamminedichloroplatinum II with high-dose
methotrexate and citrovorum factor rescue in the treatment of primary
osteosarcoma.
J Clin Oncol. 1985;3(8):1101-1104.
357. Rao BN, Rodriguez-Galindo C. Intra-arterial
cisplatin in osteosarcoma: same question, different answer. Ann
Surg Oncol. 2003;10(5):481-483.
358. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric
osteosarcoma: therapeutic strategies, results, and prognostic factors
derived from a 10-year experience. J Clin Oncol. 1990;8(12):1988-1997.
359. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma:
a randomized, prospective trial of the addition of ifosfamide and/or
muramyl tripeptide to cisplatin, doxorubicin, and high-dose
methotrexate.
J
Clin Oncol. 2005;23(9):2004-2011.
360. Kleinerman ES, Jia SF, Griffin J, Seibel NL,
Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide
in osteosarcoma: the cytokine cascade and monocyte activation following
administration. J Clin Oncol. 1992;10(8):1310-1316.
361. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated
muramyl tripeptide: a new biologic response modifier for the treatment
of osteosarcoma.
Cancer Treat Res. 1993;62:101-107.
[PubMed: 8096724]
362. Kleinerman ES, Snyder JS, Jaffe N. Influence
of chemotherapy administration on monocyte activation by liposomal
muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J
Clin Oncol. 1991;9(2):259-267.
363. MacEwen EG, Kurzman ID, Rosenthal RC, et al.
Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated
muramyl tripeptide. J Natl Cancer Inst. 1989;81
(12):935-938.
364. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma:
the addition of muramyl tripeptide to chemotherapy improves overall
survival—a report from the Children’s Oncology
Group. J Clin Oncol. 2008;26(4):633-638.
365. Bielack SS, Marina N, Ferrari S, et al. Osteosarcoma:
the same old drugs or more? J Clin Oncol. 2008;26(18):3102-3103;
author reply 3104-3105.
366. Hunsberger S, Freidlin B, Smith MA. Complexities
in interpretation of osteosarcoma clinical trial results. J
Clin Oncol. 2008;26(18):3103-3104; author reply 3104-3105.
367. Saeter G, Alvegard TA, Elomaa I, Stenwig AE,
Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities
with the T-10 protocol, with emphasis on the effects of preoperative
chemotherapy with single-agent high-dose
methotrexate: a Scandinavian
Sarcoma Group study.
J Clin Oncol. 1991;9(10):1766-1775.
368. Whelan J, Seddon B, Perisoglou M. Management
of osteosarcoma. Curr Treat Options Oncol. 2006;7(6):444-455.
369. Bramwell VH, Burgers M, Sneath R, et al. A
comparison of two short intensive adjuvant chemotherapy regimens
in operable osteosarcoma of limbs in children and young adults:
the first study of the European Osteosarcoma Intergroup. J
Clin Oncol. 1992;10(10):1579-1591.
370. Lewis IJ, Nooij MA, Whelan J, et al. Improvement
in histologic response but not survival in osteosarcoma patients
treated with intensified chemotherapy: a randomized phase III trial
of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99(2):112-128.
371. Souhami RL, Craft AW, Van der Eijken JW, et
al. Randomised trial of two regimens of chemotherapy in operable
osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350(9082):911-917.
372. Caceres E, Zaharia M. Massive preoperative
radiation therapy in the treatment of osteogenic sarcoma. Cancer. 1972;30(3):634-638.
373. de Moor NG. Osteosarcoma a review of 72 cases
treated by megavoltage radiation therapy, with or without surgery. S
Afr J Surg. 1975;13(3):137-146.
374. Beck JC, Wara WM, Bovill EG, Jr., Phillips
TL. The role of radiation therapy in the treatment of osteosarcoma. Radiology. 1976;120(1):163-165.
375. Jenkin RD. Radiation treatment of Ewing’s
sarcoma and osteogenic sarcoma. Can J Surg. 1977;20(6):530-536.
376. Gaitan-Yanguas M. A study of the response of
osteogenic sarcoma and adjacent normal tissues to radiation. Int
J Radiat Oncol Biol Phys. 1981;7(5):593-595.
377. Hristov B, Shokek O, Frassica DA. The role
of radiation treatment in the contemporary management of bone tumors. J
Natl Compr Canc Netw. 2007;5(4):456-466.
378. Merimsky O, Kollender Y, Inbar M, Meller I,
Bickels J. Palliative treatment for advanced or metastatic osteosarcoma. Isr
Med Assoc J. 2004;6(1):34-38.
379. Nagarajan R, Clohisy D, Weigel B. New paradigms
for therapy for osteosarcoma. Curr Oncol Rep. 2005;7(6):410-414.
380. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma
of the pelvis: experience of the Cooperative Osteosarcoma Study
Group. J Clin Oncol. 2003;21 (2):334-341.
381. Hershey A, Bos GD, Stevens K. Successful treatment
of spinal osteosarcoma with radiation and chemotherapy. Orthopedics. 1996;19(7):617-618.
382. DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy
for local control of osteosarcoma. Int J Radiat Oncol Biol
Phys. 2005;61(2):492-498.
383. DeLaney TF, Trofimov AV, Engelsman M, Suit
HD. Advanced-technology radiation therapy in the management of bone
and soft tissue sarcomas. Cancer Control. 2005;12(1):27-35.
384. Anderson PM, Wiseman GA, Dispenzieri A, et
al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate:
low toxicity of skeletal irradiation in patients with osteosarcoma
and bone metastases. J Clin Oncol. 2002;20(1):189-196.
385. Anderson PM, Wiseman GA, Erlandson L, et al.
Gemcitabine radiosensitization after high-dose samarium for osteoblastic
osteosarcoma. Clin Cancer Res. 2005;11(19 Pt 1):6895-6900.
386. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma
of the limb. Amputation or limb salvage in patients treated by neoadjuvant
chemotherapy. J Bone Joint Surg Br. 2002;84(1):88-92.
387. Rougraff BT, Simon MA, Kneisl JS, Greenberg
DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma
of the distal end of the femur. A long-term oncological, functional,
and quality-of-life study. J Bone Joint Surg Am. 1994;76(5):649-656.
388. Wong AC, Akahoshi Y, Takeuchi S. Limb-salvage
procedures for osteosarcoma. An alternative to amputation. Int
Orthop. 1986;10(4):245-251.
389. Eckardt JJ, Kabo JM, Kelley CM, et al. Expandable
endoprosthesis reconstruction in skeletally immature patients with
tumors. Clin Orthop Relat Res. 2000;(373):51-61.
390. Hanlon M, Krajbich JI. Rotationplasty in skeletally
immature patients. Long-term followup results. Clin Orthop
Relat Res. 1999;(358):75-82.
391. Merkel KD, Gebhardt M, Springfield DS. Rotationplasty
as a reconstructive operation after tumor resection. Clin
Orthop Relat Res. 1991; (270):231-236.
392. Winkelmann WW. Rotationplasty. Orthop
Clin North Am. 1996;27(3):503-523.
393. Winkelmann WW. Type-B-IIIa hip rotationplasty:
an alternative operation for the treatment of malignant tumors of
the femur in early childhood. J Bone Joint Surg Am. 2000;82(6):814-828.
394. Bielack SS, Jurgens H. Surgical expertise and
outcome in osteosarcoma trials. J Clin Oncol. 2004;22(12):2511;
author reply 2511-2513.
395. Ruggieri P, De Cristofaro R, Picci P, et al.
Complications and surgical indications in 144 cases of nonmetastatic
osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Clin
Orthop Relat Res. 1993(295):226-238.
396. Kempf-Bielack B, Bielack SS, Jurgens H, et
al. Osteosarcoma relapse after combined modality therapy: an analysis
of unselected patients in the Cooperative Osteosarcoma Study Group
(COSS). J Clin Oncol. 2005;23(3):559-568.
397. Kayton ML, Huvos AG, Casher J, et al. Computed
tomographic scan of the chest underestimates the number of metastatic
lesions in osteosarcoma. J Pediatr Surg. 2006;41(1):200-206;
discussion 200-206.
398. Han MT, Telander RL, Pairolero PC, et al. Aggressive
thoracotomy for pulmonary metastatic osteogenic sarcoma in children
and young adolescents. J Pediatr Surg. 1981;16(6):928-933.
399. Putnam JB, Jr., Roth JA, Wesley MN, Johnston
MR, Rosenberg SA. Survival following aggressive resection of pulmonary
metastases from osteogenic sarcoma: analysis of prognostic factors. Ann
Thorac Surg. 1983;36(5):516-523.
400. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer
WH. Improved prognosis of children with osteosarcoma metastatic
to the lung(s) at the time of diagnosis. Cancer. 1992;70(11):2722-2727.
401. Harris MB, Gieser P, Goorin AM, et al. Treatment
of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group
Study. J Clin Oncol. 1998;16(11):3641-3648.
402. Spanier SS, Shuster JJ, Vander Griend RA. The
effect of local extent of the tumor on prognosis in osteosarcoma. J
Bone Joint Surg Am. 1990;72 (5):643-653.
403. Bacci G, Briccoli A, Longhi A, et al. Treatment
and outcome of recurrent osteosarcoma: experience at Rizzoli in
235 patients initially treated with neoadjuvant chemotherapy. Acta
Oncol. 2005;44(7):748-755.
404. Bacci G, Ferrari S, Mercuri M, et al. Predictive
factors for local recurrence in osteosarcoma: 540 patients with
extremity tumors followed for minimum 2.5 years after neoadjuvant
chemotherapy. Acta Orthop Scand. 1998;69(3):230-236.
405. Bacci G, Forni C, Longhi A, et al. Local recurrence
and local control of non-metastatic osteosarcoma of the extremities:
a 27-year experience in a single institution. J Surg Oncol. 2007;96
(2):118-123.
406. Bacci G, Ruggieri P, Picci P, et al. Changing
pattern of relapse in osteosarcoma of the extremities treated with
adjuvant and neoadjuvant chemotherapy. J Chemother. 1995;7(3):230-239.
407. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse
survival in osteosarcoma of the extremities: prognostic factors
for long-term survival. J Clin Oncol. 2003;21(4):710-715.
408. Nathan SS, Gorlick R, Bukata S, et al. Treatment
algorithm for locally recurrent osteosarcoma based on local disease-free
interval and the presence of lung metastasis. Cancer. 2006;107(7):
1607-1616.
409. Brosjo O. Surgical procedure and local recurrence
in 223 patients treated 1982-1997 according to two osteosarcoma
chemotherapy protocols. The Scandinavian Sarcoma Group experience.
Acta
Orthop Scand Suppl. 1999; 285:58-61.
[PubMed: 10429624]
410. Rodriguez-Galindo C, Shah N, McCarville MB,
et al. Outcome after local recurrence of osteosarcoma: the St. Jude
Children’s Research Hospital experience (1970-2000). Cancer. 2004;100(9):
1928-1935.
411. Saeter G, Hoie J, Stenwig AE, Johansson AK,
Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic
sarcoma. Prognostic factors for long term survival. Cancer. 1995;75(5):
1084-1093.
412. Ferrari S, Bacci G, Picci P, et al. Long-term
follow-up and post-relapse survival in patients with non-metastatic
osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann
Oncol. 1997;8(8):765-771.
413. Chou AJ, Merola PR, Wexler LH, et al. Treatment
of osteosarcoma at first recurrence after contemporary therapy:
the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2005;104(10):
2214-2221.
414. Hawkins DS, Arndt CA. Pattern of disease recurrence
and prognostic factors in patients with osteosarcoma treated with
contemporary chemotherapy. Cancer. 2003;98(11):2447-2456.
415. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma
with ifosfamide: comparison of response in pediatric patients with
recurrent disease versus patients previously untreated: a Pediatric
Oncology Group study. Med Pediatr Oncol. 1995;24(2):87-92.
416. Johansen R, Nielsen OS, Keller J. Functional
outcome in sarcomas treated with limb-salvage surgery or amputation. Sarcoma. 1998;2(1):19-23.
417. Pardasaney PK, Sullivan PE, Portney LG, Mankin
HJ. Advantage of limb salvage over amputation for proximal lower
extremity tumors.
Clin Orthop Relat Res. 2006;444:201-208.
[PubMed: 16449916]
418. Postma A, Kingma A, De Ruiter JH, et al. Quality
of life in bone tumor patients comparing limb salvage and amputation
of the lower extremity. J Surg Oncol. 1992;51(1):47-51.
419. Refaat Y, Gunnoe J, Hornicek FJ, Mankin HJ.
Comparison of quality of life after amputation or limb salvage. Clin
Orthop Relat Res. 2002(397): 298-305.
420. Weddington WW, Jr., Segraves KB, Simon MA.
Psychological outcome of extremity sarcoma survivors undergoing
amputation or limb salvage. J Clin Oncol. 1985;3(10):1393-1399.
421. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz
J, McKone R, Lipshultz SE. Initial congestive heart failure, six
to ten years after doxorubicin chemotherapy for childhood cancer. J
Pediatr. 1990;116(1):144-147.
422. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female
sex and drug dose as risk factors for late cardiotoxic effects of
doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738-1743.
423. Brock PR, Bellman SC, Yeomans EC, Pinkerton
CR, Pritchard J. Cisplatin ototoxicity in children: a practical
grading system. Med Pediatr Oncol. 1991;19(4):295-300.
424. Marina NM, Poquette CA, Cain AM, Jones D, Pratt
CB, Meyer WH. Comparative renal tubular toxicity of chemotherapy
regimens including ifosfamide in patients with newly diagnosed sarcomas. J
Pediatr Hematol Oncol. 2000;22(2):112-118.
425. Williams D, Crofton PM, Levitt G. Does ifosfamide
affect gonadal function? Pediatr Blood Cancer. 2008;50(2):347-351.
426. Aung L, Gorlick RG, Shi W, et al. Second malignant
neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering
Cancer Center experience. Cancer. 2002;95(8):1728-1734.
427. Bacci G, Ferrari C, Longhi A, et al. Second
malignant neoplasm in patients with osteosarcoma of the extremities
treated with adjuvant and neoadjuvant chemotherapy. J Pediatr
Hematol Oncol. 2006;28(12):774-780.
428. Bagatell R, Gore L, Egorin MJ, et al. Phase
I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin
in pediatric patients with recurrent or refractory solid tumors:
a pediatric oncology experimental therapeutics investigators consortium
study. Clin Cancer Res. 2007;13(6):1783-1788.
429. Khanna C, Prehn J, Hayden D, et al. A randomized controlled
trial of octreotide pamoate long-acting release and carboplatin
versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation
of insulin-like growth factor suppression and chemotherapy. Clin
Cancer Res. 2002;8(7):2406-2412.
430. Mansky PJ, Liewehr DJ, Steinberg SM, et al.
Treatment of metastatic osteosarcoma with the somatostatin analog
OncoLar: significant reduction of insulin-like growth factor-1 serum
levels. J Pediatr Hematol Oncol. 2002;24(6):440-446.
431. Laverdiere C, Kolb EA, Supko JG, et al. Phase
II study of ecteinascidin 743 in heavily pretreated patients with
recurrent osteosarcoma. Cancer. 2003;98(4):832-840.
432. Anderson PM, Markovic SN, Sloan JA, et al.
Aerosol granulocyte macrophage-colony stimulating factor: a low
toxicity, lung-specific biological therapy in patients with lung
metastases. Clin Cancer Res. 1999;5(9):2316-2323.
433. Rao RD, Anderson PM, Arndt CA, Wettstein PJ,
Markovic SN. Aerosolized granulocyte macrophage colony-stimulating
factor (GM-CSF) therapy in metastatic cancer. Am J Clin
Oncol. 2003;26(5):493-498.
434. Kheradpour A, Berman E, Goker E, Lin JT, Tong
WP, Bertino JR. A phase II study of continuous infusion of trimetrexate
in patients with refractory acute leukemia.
Cancer Invest. 1995;
13(1):36-40.
[PubMed: 7834472]
435. Lacerda JF, Goker E, Kheradpour A, et al. Selective
treatment of SCID mice bearing methotrexate-transport-resistant
human acute lymphoblastic leukemia tumors with trimetrexate and
leucovorin protection.
Blood. 1995; 85(10):2675-2679.
[PubMed: 7742525]
436. Lin JT, Cashmore AR, Baker M, et al. Phase
I studies with trimetrexate: clinical pharmacology, analytical methodology,
and pharmacokinetics. Cancer Res. 1987;47(2):609-616.
437. Bodmer N, Walters DK, Fuchs B. Pemetrexed,
a multitargeted antifolate drug, demonstrates lower efficacy in
comparison to
methotrexate against osteosarcoma cell lines.
Pediatr
Blood Cancer. 2008;50(4):905-908.
438. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed:
biochemical and cellular pharmacology, mechanisms, and clinical
applications. Mol Cancer Ther. 2007;6(2):404-417.
439. Goldman ID, Zhao R. Molecular, biochemical,
and cellular pharmacology of pemetrexed. Semin Oncol. 2002;29(6
Suppl 18):3-17.
440. Bafaloukos D, Papadimitriou C, Linardou H,
et al. Combination of pegylated liposomal doxorubicin (PLD) and
paclitaxel in patients with advanced soft tissue sarcoma: a phase
II study of the Hellenic Cooperative Oncology Group. Br
J Cancer. 2004;91(9):1639-1644.
441. Davies Cde L, Lundstrom LM, Frengen J, et al.
Radiation improves the distribution and uptake of liposomal doxorubicin
(caelyx) in human osteosarcoma xenografts. Cancer Res. 2004;64
(2):547-553.
442. Judson I, Radford JA, Harris M, et al. Randomised
phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX)
versus doxorubicin in the treatment of advanced or metastatic soft
tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma
Group. Eur J Cancer. 2001;37(7):870-877.
443. Skubitz KM. Phase II trial of pegylated-liposomal
doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003;21(2):167-176.
444. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly
trastuzumab and paclitaxel therapy for metastatic breast cancer
with analysis of efficacy by HER2 immunophenotype and gene amplification. J
Clin Oncol. 2001;19(10):2587-2595.
445. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study
of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing
metastatic breast cancer. Semin Oncol. 1999;26(4
Suppl 12):78-83.
446. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based
treatment of HER2-positive breast cancer: an antibody-dependent
cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):
259-267.
447. Hudis CA. Trastuzumab—mechanism of
action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
448. Maris JM, Courtright J, Houghton PJ, et al.
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2008;50(3):581-587.
449. Mintz MB, Sowers R, Brown KM, et al. An expression
signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer
Res. 2005;65(5):1748-1754.
450. Iguchi T, Miyakawa Y, Saito K, et al. Zoledronate-induced
S phase arrest and apoptosis accompanied by DNA damage and activation
of the ATM/Chk1/cdc25 pathway in human osteosarcoma
cells. Int J Oncol. 2007;31(2):285-291.
451. Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli
F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated
effector cells. Cell Immunol. 2007;249(2):63-72.
452. Houghton PJ, Morton CL, Kolb EA, et al. Initial
testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric
preclinical testing program. Pediatr Blood Cancer. 2008;50(4):799-805.
453. Houghton PJ, Morton CL, Tucker C, et al. The
pediatric preclinical testing program: description of models and
early testing results. Pediatr Blood Cancer. 2007;49(7):928-940.
454. Kolb EA, Gorlick R, Houghton PJ, et al. Initial
testing (stage 1) of a monoclonal antibody (SCH 717454) against
the IGF-1 receptor by the pediatric preclinical testing program. Pediatr
Blood Cancer. 2008;50(6):1190-1197.
455. Kolb EA, Gorlick R, Houghton PJ, et al. Initial
testing of
dasatinib by the pediatric preclinical testing program.
Pediatr
Blood Cancer. 2008; 50(6):1198-1206.
[PubMed: 17914733]
456. Lock R, Carol H, Houghton PJ, et al. Initial
testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical
testing program. Pediatr Blood Cancer. 2008;50(6):1181-1189.
457. Neale G, Su X, Morton CL, et al. Molecular
characterization of the pediatric preclinical testing panel. Clin
Cancer Res. 2008;14(14):4572-4583.
458. Tajbakhsh M, Houghton PJ, Morton CL, et al.
Initial testing of cisplatin by the pediatric preclinical testing
program. Pediatr Blood Cancer. 2008;50(5):992-1000.
459. Whiteford CC, Bilke S, Greer BT, et al. Credentialing
preclinical pediatric xenograft models using gene expression and
tissue microarray analysis. Cancer Res. 2007;67(1):32-40.
460. Paoloni MC, Khanna C. Comparative oncology today. Vet
Clin North Am Small Anim Pract. 2007;37(6):1023-1032; v.
461. Paoloni M, Khanna C. Translation of new cancer
treatments from pet dogs to humans. Nat Rev Cancer. 2008;8(2):147-156.